血清SV2A、Aβ42、Tau蛋白、p-Tau181水平对阿尔茨海默病诊断及病情评估的价值研究OA
Study on the value of serum SV2A,Aβ42,Tau protein,p-Tau181 in the diagnosis and condition evaluation of Alzhei-mer's disease
目的 探讨血清突触囊泡蛋白2A(SV2A)水平在阿尔茨海默病(AD)诊断及病情评估中的价值.方法 选取2021年1月—2023年12月中国人民解放军联勤保障部队第九○四医院神经内科收治的AD患者130例为AD组,根据不同病情程度将AD患者分为轻度60例、中度40例、重度30例,另选取同期医院健康体检者20例为健康对照组.采用酶联免疫吸附试验(ELISA)检测血清SV2A、β-淀粉样蛋白42(Aβ42)、Tau蛋白、磷酸化Tau蛋白181(p-Tau181)水平;Pearson相关系数分析血清SV2A水平与临床指标的相关性;多因素Logistic回归分析发生重度AD的影响因素;受试者工作特征(ROC)曲线评估血清SV2A水平对重度AD的预测效能.结果 AD组血清SV2A、Aβ42水平低于健康对照组,血清Tau蛋白、p-Tau181水平高于健康对照组(t/P=12.682/<0.001、10.875/<0.001、15.923/<0.001、20.341/<0.001);AD 患者血清 SV2A、Aβ42 水平比较,轻度>中度>重度(F/P=56.789/<0.001、32.145/<0.001),血清Tau蛋白、p-Tau181水平比较,轻度<中度<重度(F/P=45.670/<0.001、68.912/<0.001);AD患者血清SV2A水平与MMSE评分、MoCA评分、海马体积、受教育年限、体质量指数(BMI)呈正相关(r/P=0.652/<0.001、0.625/<0.001、0.502/<0.001、0.518/<0.001、0.210/0.023),与CDR评分、ADL评分、NPI评分、年龄、病程、吸烟史、高血压呈负相关(r/P=-0.721/<0.001、-0.681/<0.001、-0.552/<0.001、-0.435/<0.001、-0.583/<0.001、-0.278/0.030、-0.231/0.049).多因素Logistic回归分析显示,年龄大、有吸烟史、有高血压、CDR评分高、ADL评分高、Tau蛋白水平高、p-Tau181水平高是患者发生重度 AD 的独立危险因素[OR(95%CI)=1.085(1.022~1.152)、2.282(1.135~4.589)、2.078(1.045~4.132)、3.512(1.732~7.158)、1.033(1.009~1.057)、1.021(1.005~1.037)、1.053(1.011~1.096)],受教育年限长、MMSE评分高、MoCA评分高、海马体积大、SV2A水平高、Aβ42水平高为独立保护因素[OR(95%CI)=0.855(0.762~0.959)、0.831(0.726~0.951)、0.851(0.756~0.959)、0.439(0.232~0.831)、0.959(0.932~0.987)、0.995(0.991~0.999)];血清SV2A、Aβ42、Tau蛋白、p-Tau181水平单独及联合预测重度AD的曲线下面积(AUC)分别为0.856、0.782、0.815、0.832、0.923,四者联合显著高于各指标单独预测的价值(Z/P=2.154/0.031、2.345/0.019、2.012/0.044、1.987/0.047).结论 血清SV2A水平与AD病情严重程度及认知功能密切相关,可作为辅助诊断及病情评估的潜在生物标志物.
Objective To explore the value of serum synaptic vesicle protein 2A(SV2A)level in the diagnosis and condition assessment of Alzheimer's disease(AD).Methods A total of 130 AD patients(60 cases of mild,40 cases of mod-erate and 30 cases of severe)who visited the Department of Neurology of the 904th Hospital of the Joint Logistic Support Force of the People's Liberation Army of China from January 2021 to December 2023 and 20 healthy controls were included.The levels of serum SV2A,Aβ42,Tau protein and p-Tau181 were detected by enzyme-linked immunosorbent assay(ELISA).The correlations were analyzed in combination with cognitive function scales(MMSE,MoCA),disease severity scales(CDR,ADL,NPI)and hippocampal volume.The diagnostic efficacy of SV2A was evaluated by ROC curve.Multiple linear regres-sion is used to screen for independent influencing factors.Results Compared with the healthy control group,the levels of se-rum SV2A and A β4 2 in the AD group decreased,but the levels of Tau protein and p-Tau181 increased in the AD group(t/P=12.682/<0.001,10.875/<0.001,15.923/<0.001,20.341/<0.001).In the AD group,the levels of serum SV2A and Aβ42 in patients with mild,moderate and severe AD decreased successively,but the levels of Tau protein and p-Tau181 increased successively(F/P=56.789/<0.001,32.145/<0.001,45.670/<0.001,68.912/<0.001).The serum SV2A level showed a decreasing trend with the aggravation of AD severity(150.45±15.87 ng/mL in the healthy control group vs 80.78±13.45 ng/mL in the severe AD group,P<0.001),which was significantly positively correlated with MMSE and MoCA scores(r=0.652,0.625,both P<0.001),and negatively correlated with CDR,ADL,NPI scores and disease course(r=-0.721 to-0.552,all P<0.001),and was positively correlated with hippocampal volume(r=0.502,P<0.001).Serum SV2A level(OR=0.821,95%CI.0.756-0.889,P<0.001),age(OR=1.123,95%CI:1.087-1.160,P<0.001),MMSE score(OR=0.895,95%CI:0.856-0.934,P<0.001),ADL score(OR=1.056,95%CI:1.023-1.089,P<0.001),and hippocampal volume(OR=0.912,95%CI:0.876-0.948,P<0.001)were independ-ent risk factors for the progression of AD.The ROC curve further demonstrated that the AUC for predicting the prevalence of AD by combining serum SV2A level,age,MMSE score,ADL score and hippocampal volume increased to 0.905(95%CI:0.856-0.954,P<0.001),which was significantly higher than that of a single indicator(P<0.001).Conclusion The level of se-rum SV2A is closely related to the severity of AD and cognitive function,and has high efficacy in the diagnosis of AD.It can be used as a potential biomarker for auxiliary diagnosis and disease assessment.
万琦;朱金;吴佳羽;曹君冬
214044 江苏无锡,中国人民解放军联勤保障部队第九○四医院神经内科214044 江苏无锡,中国人民解放军联勤保障部队第九○四医院神经内科214044 江苏无锡,中国人民解放军联勤保障部队第九○四医院神经内科214044 江苏无锡,中国人民解放军联勤保障部队第九○四医院神经内科
医药卫生
阿尔茨海默病突触囊泡蛋白2Aβ-淀粉样蛋白42Tau蛋白磷酸化Tau蛋白181诊断效能
Alzheimer's diseaseSynaptic vesicle protein 2AAβ42Tau proteinp-Tau181Diagnostic efficacy
《疑难病杂志》 2026 (1)
42-47,6
江苏省卫生健康委科研项目(M2021090) Scientific Research Project of Jiangsu Provincial Health Commission(M2021090)
评论